chlorambucil has been researched along with Preleukemia in 7 studies
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.
Preleukemia: Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "A new case is reported here of acute myeloid leukemia after chlorambucil therapy for multiple sclerosis." | 7.67 | [Acute leukemia secondary to the treatment of multiple sclerosis with chlorambucil]. ( Aymard, JP; Barroche, G; Conroy, T; Humbert, JC; Lederlin, P; Streiff, F; Witz, F, 1985) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "A new case is reported here of acute myeloid leukemia after chlorambucil therapy for multiple sclerosis." | 3.67 | [Acute leukemia secondary to the treatment of multiple sclerosis with chlorambucil]. ( Aymard, JP; Barroche, G; Conroy, T; Humbert, JC; Lederlin, P; Streiff, F; Witz, F, 1985) |
| "A 55-year-old man was treated during 22 months with chlorambucil (total dose : 4 218 g) for glomerulonephritis." | 3.66 | [Acute leukaemia during immunosuppressive treatment. One case (author's transl)]. ( Blanc, AP; Carcassonne, Y; Dalivoust, P; Gastaut, JA; Murisasco, A; Sébahoun, G, 1981) |
| "Of 602 patients treated for non-Hodgkin's lymphomas, 9 developed overt acute nonlymphocytic leukemia or preleukemia with refractory cytopenia and cytogenetic abnormalities of the bone marrow." | 1.27 | Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. ( Ersbøll, J; Keiding, N; Larsen, MS; Larsen, SO; Nissen, NI; Pedersen-Bjergaard, J; Philip, P; Schultz, H; Sørensen, HM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (71.43) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanc, AP | 1 |
| Gastaut, JA | 1 |
| Sébahoun, G | 1 |
| Dalivoust, P | 1 |
| Murisasco, A | 1 |
| Carcassonne, Y | 1 |
| Bauer, A | 1 |
| Garbe, C | 1 |
| Detmar, M | 1 |
| Kreuser, ED | 1 |
| Gollnick, H | 1 |
| Nand, S | 1 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 1 |
| Hoffman, R | 1 |
| Wasserman, LR | 1 |
| Tchernia, G | 1 |
| Mielot, F | 1 |
| Subtil, E | 1 |
| Parmentier, C | 1 |
| Aymard, JP | 1 |
| Witz, F | 1 |
| Conroy, T | 1 |
| Lederlin, P | 1 |
| Humbert, JC | 1 |
| Barroche, G | 1 |
| Streiff, F | 1 |
| Pedersen-Bjergaard, J | 1 |
| Ersbøll, J | 1 |
| Sørensen, HM | 1 |
| Keiding, N | 1 |
| Larsen, SO | 1 |
| Philip, P | 1 |
| Larsen, MS | 1 |
| Schultz, H | 1 |
| Nissen, NI | 1 |
2 reviews available for chlorambucil and Preleukemia
| Article | Year |
|---|---|
[Multicentric reticulohistiocytosis and myelodysplastic syndrome].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Diagnosis, Differential; | 1994 |
Natural history and management of polycythemia vera.
Topics: Acute Disease; Adult; Antineoplastic Agents; Bloodletting; Cell Transformation, Neoplastic; Chloramb | 1979 |
5 other studies available for chlorambucil and Preleukemia
| Article | Year |
|---|---|
[Acute leukaemia during immunosuppressive treatment. One case (author's transl)].
Topics: Blood Cell Count; Chlorambucil; Glomerulonephritis; Humans; Leukemia, Myeloid, Acute; Male; Middle A | 1981 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
Acute myeloblastic leukemia after immunodepressive therapy for primary nonmalignant disease.
Topics: Arthritis, Rheumatoid; Bone Marrow; Bone Marrow Cells; Chlorambucil; Cyclophosphamide; Diagnosis, Di | 1976 |
[Acute leukemia secondary to the treatment of multiple sclerosis with chlorambucil].
Topics: Adult; Alkylating Agents; Chlorambucil; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid, | 1985 |
Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
Topics: Acute Disease; Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Prot | 1985 |